Related Experiment Video
Updated: Sep 28, 2026

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
Published on: July 21, 2023
Enhanced activities and gene expression of phosphodiesterase types 3 and 4 in pressure-induced congestive heart
Koki Takahashi1, Tomohiro Osanai, Takao Nakano
1Second Department of Internal Medicine, Hirosaki University School of Medicine, 5 Zaifu-cho, Hirosaki 036-8562, Japan.
Insights
Phosphodiesterase 3 and 4 (PDE3 and PDE4) gene expression and activity increase in salt-induced heart failure. This suggests PDEs contribute to the development and worsening of congestive heart failure (CHF).
Area of Science:
- Cardiovascular Physiology
- Molecular Biology
- Pharmacology
Background:
- Phosphodiesterase (PDE) expression varies in heart conditions, being downregulated in failing hearts and upregulated in hypertrophy.
- Understanding PDE regulation in heart failure is crucial for therapeutic development.
Purpose of the Study:
- To investigate the time course of phosphodiesterase 3 and 4 (PDE3 and PDE4) gene expression and activity.
- To determine the role of PDEs in salt-induced hypertension, left ventricular hypertrophy, and congestive heart failure (CHF).
Main Methods:
- Dahl salt-sensitive (DS) and salt-resistant (DR) rats were fed an 8% NaCl diet.
- PDE3 and PDE4 activity, mRNA expression, cardiac cyclic adenosine monophosphate, and plasma nitric oxide were measured at 11 and 18 weeks.
Main Results:
- PDE4 activity was higher in DS rats at 11 weeks (hypertrophy stage).
- At 18 weeks (CHF stage), both PDE3 and PDE4 activity and mRNA expression were elevated in DS rats compared to DR rats.
- Cardiac cyclic adenosine monophosphate and plasma nitric oxide levels changed differentially over time in DS rats.
Conclusions:
- PDE3 and PDE4 gene expression and activity are augmented during the hypertrophic and CHF stages in this salt-induced heart failure model.
- Enhanced PDE3 and PDE4 activity appear to contribute to the development and exacerbation of CHF.
Abstract:
Phosphodiesterase (PDE) was shown to be downregulated in the failing hearts of transplant recipients, while it was upregulated in hypertrophied hearts induced by isoproterenol and calsequesterin overexpression. We examined the time course of gene expression and the activity of PDE3 and PDE4 in an animal model of salt-induced hypertension, left ventricular hypertrophy, and congestive heart failure (CHF). Dahl salt-sensitive (DS, n = 25) and salt-resistant rats (DR, n = 25) were fed with an 8% NaCl diet after the age of 6 weeks. At 11 weeks (hypertension and hypertrophy stage in DS), PDE4 activity in the heart was higher in DS than in DR. At 18 weeks (hypertension and CHF stage in DS), both PDE3 and PDE4 activity in both the heart and aorta was approximately twofold higher in DS than in DR. The ratios of PDE3 and PDE4 mRNA to GAPDH mRNA in the heart were both approximately twofold higher in DS than in DR at 11 and 18 weeks. The cardiac cyclic adenosine monophosphate content and plasma nitric oxide concentration were higher in DS than in DR at 11 weeks but both of them were lower in DS than in DR at 18 weeks of age. In this animal model, gene expressions of PDE3 and PDE4 were augmented from the hypertrophic stage. PDE3 and PDE4 activities were subsequently enhanced in the CHF stage and seemed to contribute to the development and exacerbation of CHF.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Heart Failure V: Medical Management
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
